125 related articles for article (PubMed ID: 26453803)
1. Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques.
Wong K; Briddon SJ; Holliday ND; Kerr ID
Biochim Biophys Acta; 2016 Jan; 1863(1):19-29. PubMed ID: 26453803
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Meyer zu Schwabedissen HE; Kroemer HK
Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
[TBL] [Abstract][Full Text] [Related]
3. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
Henriksen U; Gether U; Litman T
J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
[TBL] [Abstract][Full Text] [Related]
4. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
Mizuarai S; Aozasa N; Kotani H
Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
[TBL] [Abstract][Full Text] [Related]
5. Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABCG sequences.
Haider AJ; Cox MH; Jones N; Goode AJ; Bridge KS; Wong K; Briggs D; Kerr ID
Biosci Rep; 2015 Jul; 35(4):. PubMed ID: 26294421
[TBL] [Abstract][Full Text] [Related]
6. ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans.
Nakayama A; Matsuo H; Takada T; Ichida K; Nakamura T; Ikebuchi Y; Ito K; Hosoya T; Kanai Y; Suzuki H; Shinomiya N
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1091-7. PubMed ID: 22132962
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A.
Ejendal KF; Hrycyna CA
Mol Pharmacol; 2005 Mar; 67(3):902-11. PubMed ID: 15598974
[TBL] [Abstract][Full Text] [Related]
8. A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions.
Saito H; Hirano H; Nakagawa H; Fukami T; Oosumi K; Murakami K; Kimura H; Kouchi T; Konomi M; Tao E; Tsujikawa N; Tarui S; Nagakura M; Osumi M; Ishikawa T
J Pharmacol Exp Ther; 2006 Jun; 317(3):1114-24. PubMed ID: 16489126
[TBL] [Abstract][Full Text] [Related]
9. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Galetti M; Petronini PG; Fumarola C; Cretella D; La Monica S; Bonelli M; Cavazzoni A; Saccani F; Caffarra C; Andreoli R; Mutti A; Tiseo M; Ardizzoni A; Alfieri RR
PLoS One; 2015; 10(11):e0141795. PubMed ID: 26536031
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
11. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane.
Diop NK; Hrycyna CA
Biochemistry; 2005 Apr; 44(14):5420-9. PubMed ID: 15807535
[TBL] [Abstract][Full Text] [Related]
12. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
[TBL] [Abstract][Full Text] [Related]
13. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.
Henriksen U; Fog JU; Litman T; Gether U
J Biol Chem; 2005 Nov; 280(44):36926-34. PubMed ID: 16107343
[TBL] [Abstract][Full Text] [Related]
14. The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranes.
Dezi M; Fribourg PF; Di Cicco A; Arnaud O; Marco S; Falson P; Di Pietro A; Lévy D
Biochim Biophys Acta; 2010 Nov; 1798(11):2094-101. PubMed ID: 20691149
[TBL] [Abstract][Full Text] [Related]
15. Effects of the gout-causing Q141K polymorphism and a CFTR ΔF508 mimicking mutation on the processing and stability of the ABCG2 protein.
Sarankó H; Tordai H; Telbisz Á; Özvegy-Laczka C; Erdős G; Sarkadi B; Hegedűs T
Biochem Biophys Res Commun; 2013 Jul; 437(1):140-5. PubMed ID: 23800412
[TBL] [Abstract][Full Text] [Related]
16. The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.
Ejendal KF; Diop NK; Schweiger LC; Hrycyna CA
Protein Sci; 2006 Jul; 15(7):1597-607. PubMed ID: 16815914
[TBL] [Abstract][Full Text] [Related]
17. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
18. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
Ozvegy-Laczka C; Köblös G; Sarkadi B; Váradi A
Biochim Biophys Acta; 2005 Feb; 1668(1):53-63. PubMed ID: 15670731
[TBL] [Abstract][Full Text] [Related]
19. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity.
Xu J; Peng H; Chen Q; Liu Y; Dong Z; Zhang JT
Cancer Res; 2007 May; 67(9):4373-81. PubMed ID: 17483351
[TBL] [Abstract][Full Text] [Related]
20. ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion.
Takada T; Ichida K; Matsuo H; Nakayama A; Murakami K; Yamanashi Y; Kasuga H; Shinomiya N; Suzuki H
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):275-81. PubMed ID: 24940679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
